XML 68 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions and Divestitures (Details)
€ in Millions, $ in Millions
Oct. 30, 2020
USD ($)
Oct. 30, 2020
EUR (€)
Aug. 07, 2020
EUR (€)
brand
Feb. 13, 2020
USD ($)
Jan. 03, 2020
USD ($)
Jul. 02, 2019
USD ($)
May 17, 2019
USD ($)
Apr. 01, 2019
USD ($)
Sanofi Brands                
Business Acquisition [Line Items]                
Number of brands acquired | brand     3          
Purchase price paid | €     € 52.0          
Steripod                
Business Acquisition [Line Items]                
Purchase price paid         $ 26.0      
Developed product technology, formulations, and product rights | Generic Product Acquisition                
Business Acquisition [Line Items]                
Useful life of intangible assets           20 years 20 years  
Payments to acquire the ANDA           $ 49.0 $ 15.7  
Developed product technology, formulations, and product rights | Budesonide Nasal Spray and Triamcinolone Nasal Spray                
Business Acquisition [Line Items]                
Useful life of intangible assets               10 years
Payments to acquire the ANDA               $ 14.0
Income from sales owned by the company (percent)               100.00%
Brand | Dexsil                
Business Acquisition [Line Items]                
Intangible assets acquired       $ 8.0        
Useful life of intangible assets       25 years        
Brand | Steripod                
Business Acquisition [Line Items]                
Intangible assets acquired         $ 25.1      
Useful life of intangible assets         25 years      
Subsequent Event | Sanofi Brands                
Business Acquisition [Line Items]                
Purchase price paid $ 62.0 € 53.3